Cardiovascular magnetic resonance evaluation of the effects of Niaspan [niacin] on regression of atherosclerosis and restoration of endothelial function

Trial Profile

Cardiovascular magnetic resonance evaluation of the effects of Niaspan [niacin] on regression of atherosclerosis and restoration of endothelial function

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Niacin (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Low HDL cholesterol
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 Nov 2009 Results published in Journal of the American College of Cardiology.
    • 03 Nov 2009 Status changed from active, no longer recruiting to completed, as reported in the Journal of the American College of Cardiology.
    • 30 Jan 2007 Status changed from recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top